"Designing Growth Strategies is in our DNA"

North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal Antibodies, Antineoplastic, Hedgehog Pathway Inhibitors, and Others), By Route of Administration (Oral, Topical, and Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Forecast, 2021-2028

Last Updated: January 27, 2025 | Format: PDF | Report ID: FBI106348

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. New Product Launches, Key Players
    2. Key Industry Developments Partnerships, Mergers, and Acquisitions
    3. Overview of Regulatory Scenario for the Approval of Drugs in the U.S.
    4. Impact of COVID 19 on the Market
  5. North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Monoclonal Antibodies
      2. Antineoplastic
      3. Hedgehog Pathway Inhibitors
      4. Others
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Topical
      3. Parenteral
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  6. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2020)
    3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, Financials (based on availability))
      1. F. Hoffmann-La Roche Ltd.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      2. Merck & Co., Inc.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      3. Sanofi
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      4. Eli Lilly and Company
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      5. Regeneron Pharmaceuticals Inc.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      6. Bausch Health Companies Inc.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      7. Sun Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      8. Amgen Inc.
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
      9. LEO Pharma A/S
        1. Overview,
        2. Products,
        3. SWOT,
        4. Recent Developments,
        5. Strategies,
        6. Financials (based on availability)
  7. Strategic Recommendations
Read Less

Table 01: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue (USD million) Forecast, by Country, 2017-2028

Table 02: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue (USD million) Forecast, By Drug Class, 2017-2028

Table 03: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue (USD million) forecast, by Route of Administration, 2017-2028

Table 04: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue (USD million) forecast, by Distribution Channel, 2017-2028

Figure 01: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Value (USD million), by Country, 2020 & 2028

Figure 02: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue Share (%), by Country, 2020

Figure 03: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue Share (%), by Drug Class, 2020

Figure 04: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue Share (%), by Route of Administration, 2020

Figure 05: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Revenue Share (%), by Distribution Channel, 2020

Figure 06: North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Share Analysis (%), By Company, 2020

  • 2017-2028
  • 2020
  • 2017-2019
  • 122
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase